A carregar...
Efficacy of Ruxolitinib for Myelofibrosis
INTRODUCTION: The discovery of the activating JAK2V617F mutation in patients with myelofibrosis (MF) led to the development of JAK2 inhibitors. The first such inhibitor to enter clinical trials was ruxolitinib. This review summarizes pre-clinical and clinical data of ruxolitinib in MF. AREAS COVERED...
Na minha lista:
| Publicado no: | Expert Opin Pharmacother |
|---|---|
| Main Authors: | , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
2014
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4824286/ https://ncbi.nlm.nih.gov/pubmed/24856675 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1517/14656566.2014.923404 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|